Posted by Michael Wonder on 11 Feb 2018
Roche wins UK watchdog's nod for lymphoma drug after initial snub
10 February 2018 - Britain’s healthcare watchdog recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting the Swiss drug maker’s medicine last year as too expensive.
NICE recommended Gazyvaro, also called Gazyva, for use by the National Health Service (NHS) with chemotherapy in patients with higher risk of relapse. The company must provide the drug at a discount, NICE wrote.
The decision will affect about 1,200 people annually, Roche said on Friday. About 1,900 people are diagnosed with follicular lymphoma a year in Britain.
